Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

A new botulinum toxin potentially bioequivalent to onabotulinumtoxinA: are there any differences at all?

Yang GH, Jung HH.

Dermatol Surg. 2013 Jan;39(1 Pt 2):165-70. doi: 10.1111/dsu.12073. Review. No abstract available. Erratum in: Dermatol Surg. 2013 Jun;39(6):965.

PMID:
23301820
[PubMed - indexed for MEDLINE]
2.

New neurotoxins on the horizon.

Freeman SR, Cohen JL.

Aesthet Surg J. 2008 May-Jun;28(3):325-30. doi: 10.1016/j.asj.2008.03.006. Review.

PMID:
19083544
[PubMed - indexed for MEDLINE]
3.

Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment.

Rana AQ, Shah R.

Acta Neurol Belg. 2012 Mar;112(1):95-6. doi: 10.1007/s13760-012-0019-z. Epub 2012 Jan 24.

PMID:
22427299
[PubMed - indexed for MEDLINE]
4.

Advances in the use of botulinum neurotoxins in facial esthetics.

Flynn TC.

J Cosmet Dermatol. 2012 Mar;11(1):42-50. doi: 10.1111/j.1473-2165.2011.00593.x. Review.

PMID:
22360334
[PubMed - indexed for MEDLINE]
5.

Botulinum toxin versus submandibular duct relocation for severe drooling.

Scheffer AR, Erasmus C, VAN Hulst K, VAN Limbeek J, Rotteveel JJ, Jongerius PH, van den Hoogen FJ.

Dev Med Child Neurol. 2010 Nov;52(11):1038-42. doi: 10.1111/j.1469-8749.2010.03713.x.

PMID:
20561006
[PubMed - indexed for MEDLINE]
6.

[Indications and management of botulinum toxin].

Singer C.

Rev Neurol. 1999 Jul 16-31;29(2):157-62. Review. Spanish.

PMID:
10528331
[PubMed - indexed for MEDLINE]
7.

Comparative study of biological activity of four botulinum toxin type A preparations in mice.

Chung ME, Song DH, Park JH.

Dermatol Surg. 2013 Jan;39(1 Pt 2):155-64. doi: 10.1111/dsu.12071.

PMID:
23301819
[PubMed - indexed for MEDLINE]
8.

Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.

Torii Y, Akaike N, Harakawa T, Kato K, Sugimoto N, Goto Y, Nakahira S, Kohda T, Kozaki S, Kaji R, Ginnaga A.

J Pharmacol Sci. 2011;117(4):275-85. Epub 2011 Nov 26.

PMID:
22123262
[PubMed - indexed for MEDLINE]
Free Article
9.

Botulinum neurotoxin A: a review.

Berry MG, Stanek JJ.

J Plast Reconstr Aesthet Surg. 2012 Oct;65(10):1283-91. doi: 10.1016/j.bjps.2012.04.016. Epub 2012 Apr 30. Review.

PMID:
22552262
[PubMed - indexed for MEDLINE]
10.

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S.

Eur Urol. 2011 Oct;60(4):784-95. doi: 10.1016/j.eururo.2011.07.001. Epub 2011 Jul 13. Review.

PMID:
21782318
[PubMed - indexed for MEDLINE]
11.

Consistent biochemical data are essential for comparability of botulinum toxin type A products.

Pickett A.

Drugs R D. 2011;11(1):97-8; author reply 98-9. doi: 10.2165/11590750-000000000-00000. No abstract available.

PMID:
21410299
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Handling botulinum toxins: an updated literature review.

Trindade De Almeida AR, Secco LC, Carruthers A.

Dermatol Surg. 2011 Nov;37(11):1553-65. doi: 10.1111/j.1524-4725.2011.02087.x. Epub 2011 Jul 21. Review.

PMID:
21777338
[PubMed - indexed for MEDLINE]
13.

Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

Frevert J.

Drugs R D. 2010;10(2):67-73. doi: 10.2165/11584780-000000000-00000.

PMID:
20698714
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ.

J Neuroimmunol. 2011 Aug 15;237(1-2):66-72. doi: 10.1016/j.jneuroim.2011.06.005. Epub 2011 Jul 6.

PMID:
21737146
[PubMed - indexed for MEDLINE]
15.

Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.

Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O.

Br J Ophthalmol. 2003 Jan;87(1):54-6.

PMID:
12488263
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.

Baş B, Ozan B, Muğlali M, Celebi N.

Med Oral Patol Oral Cir Bucal. 2010 Jul 1;15(4):e649-52.

PMID:
20173718
[PubMed - indexed for MEDLINE]
Free Article
17.

Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm.

Wabbels B, Jost WH, Roggenkämper P.

J Neural Transm. 2011 Jun;118(6):925-43. doi: 10.1007/s00702-010-0546-9. Epub 2011 Jan 9. Review.

PMID:
21221669
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The analgesic potential of clostridial neurotoxin derivatives.

Foster KA.

Expert Opin Investig Drugs. 2004 Nov;13(11):1437-43. Review.

PMID:
15500391
[PubMed - indexed for MEDLINE]
19.

[Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].

Winterhoff J, Laskawi R.

HNO. 2012 Jun;60(6):479-83. doi: 10.1007/s00106-012-2497-y. German.

PMID:
22669435
[PubMed - indexed for MEDLINE]
20.

Botulinum toxin type A therapy for blepharospasm.

Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004900. Review.

PMID:
15674969
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk